European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

HERZLIYA, Israel and CALGARY, AB, April 7, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a ...

New Delhi: Pharmaceutical major Novartis Healthcare has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the ...

(Image Credits: Pixabay) Novartis on Thursday announced the US ... and each person’s journey is unique, the pharma major stated. “My son was diagnosed with IgA nephropathy long before there ...

When Novartis bought kidney disease biotech Chinook ... said during a recent interview with Fierce Pharma. In the phase 3 Align trial, Vanrafia led to a 36% reduction in proteinuria as measured ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price target of CHF115.00. The company’s shares opened today ...

Roni Kamhi, CEO BI Sky Global and COO of Innocan Pharma commented: "We are very pleased with our outstanding results and especially our strong revenue growth. At BI Sky Global we are clearly ...

BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...

Filing of intimation received from RTA for the loss of share certificate u/r 39(3) dated September 07, 2024 ...

Looking ahead, this article highlights the key trends expected to shape the regulatory landscape of pharmaceutical manufacturing in 2025. Regulatory agencies—including the U.S. Food and Drug ...